Advertisement

Arrhythmia

  • Takekazu Miyoshi
Chapter

Abstract

Arrhythmias are by far the most common complication in adults with structural heart disease and complicate a substantial number of pregnancies. Most arrhythmias are benign, but therapy should be initiated for pregnant women with severe symptoms or hemodynamically unstable arrhythmias. Arrhythmias are also an important trigger for the occurrence of heart failure. All antiarrhythmic drugs undergo placental transfer to varying degrees, and there is potential for fetal effects. Therefore, the lowest effective dose of the medication should be chosen. Since atrial flutter/fibrillation, atrial tachycardia, ventricular tachycardia, and complete atrioventricular block may cause significant hemodynamic changes that may seriously affect the mother and fetus, appropriate diagnosis and emergency treatment are commonly required. Catheter ablation in pregnant women should be undertaken in a situation in which reasonable medication is ineffective. Pregnant women who present with unstable ventricular arrhythmias and at high risk for sudden cardiac death during pregnancy may be candidates for implantable cardioverter-defibrillator implantation. Since cardiac arrest is more common in the postpartum period compared with during pregnancy and labor, temporary use of a wearable cardioverter defibrillator in the postpartum period may be suitable for patients at higher risk of ventricular arrhythmias and long QT syndrome. This chapter reviews different types of arrhythmias and gives an overview of the current treatment strategies.

Keywords

Antiarrhythmic drug Arrhythmia Bradycardia Implantable cardioverter defibrillator Pregnancy Tachycardia 

References

  1. 1.
    Franz MR, Cima R, Wang D, Profitt D, Kurz R (1992) Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation 86:968–978CrossRefGoogle Scholar
  2. 2.
    Ninio DM, Saint DA (2008) The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis. Prog Biophys Mol Biol 97:401–416CrossRefGoogle Scholar
  3. 3.
    Soliman EZ, Elsalam MA, Li Y (2010) The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace 12:261–265CrossRefGoogle Scholar
  4. 4.
    Odening KE, Choi BR, Liu GX, Hartmann K, Ziv O, Chaves L, Schofield L, Centracchio J, Zehender M, Peng X, Brunner M, Koren G (2012) Estradiol promotes sudden cardiac death in transgenic long QT type 2 rabbits while progesterone is protective. Heart Rhythm 9:823–832CrossRefGoogle Scholar
  5. 5.
    Roberts JM, Insel PA, Goldfien A (1981) Regulation of myometrial adrenoreceptors and adrenergic response by sex steroids. Mol Pharmacol 20:52–58PubMedGoogle Scholar
  6. 6.
    Enriquez AD, Economy KE, Tedrow UB (2014) Contemporary management of arrhythmias during pregnancy. Circ Arrhythm Electrophysiol 7:961–967CrossRefGoogle Scholar
  7. 7.
    Opotowsky AR, Siddiqi OK, Webb GD (2009) Trends in hospitalizations for adults with congenital heart disease in the U.S. J Am Coll Cardiol 28(54):460–467CrossRefGoogle Scholar
  8. 8.
    Walsh EP, Cecchin F (2007) Arrhythmias in adult patients with congenital heart disease. Circulation 30(115):534–545CrossRefGoogle Scholar
  9. 9.
    Triedman JK (2002) Arrhythmias in adults with congenital heart disease. Heart 87:383–389CrossRefGoogle Scholar
  10. 10.
    Bhatt AB, Foster E, Kuehl K, Alpert J, Brabeck S, Crumb S, Davidson WR Jr, Earing MG, Ghoshhajra BB, Karamlou T, Mital S, Ting J, Tseng ZH, American Heart Association Council on Clinical Cardiology (2015) Congenital heart disease in the older adult: a scientific statement from the American Heart Association. Circulation 26(131):1884–1931CrossRefGoogle Scholar
  11. 11.
    Silka MJ, Bar-Cohen Y (2012) A contemporary assessment of the risk for sudden cardiac death in patients with congenital heart disease. Pediatr Cardiol 33:452–460CrossRefGoogle Scholar
  12. 12.
    Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, Fernandes SM, Beauchesne L, Therrien J, Chetaille P, Gordon E, Vonder Muhll I, Cecchin F (2008) Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 22(117):363–370CrossRefGoogle Scholar
  13. 13.
    Miyoshi T, Maeno Y, Sago H, Inamura N, Yasukouchi S, Kawataki M, Horigome H, Yoda H, Taketazu M, Shozu M, Nii M, Kato H, Hagiwara A, Omoto A, Shimizu W, Shiraishi I, Sakaguchi H, Nishimura K, Nakai M, Ueda K, Katsuragi S, Ikeda T (2015) Fetal bradyarrhythmia associated with congenital heart defects - nationwide survey in Japan. Circ J 79:854–861CrossRefGoogle Scholar
  14. 14.
    Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, Budts W, Zwinderman AH, Van Gelder IC, Mulder BJ (2012) Sudden cardiac death in adult congenital heart disease. Circulation 126(16):1944–1954CrossRefGoogle Scholar
  15. 15.
    Li JM, Nguyen C, Joglar JA, Hamdan MH, Page RL (2008) Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 31:538–541CrossRefGoogle Scholar
  16. 16.
    Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW Jr, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ, American College of Cardiology, American Heart Association Task Force on Practice Guidelines, European Society of Cardiology Committee for Practice Guidelines, Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias (2003) ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias). Circulation 108:1871–1909CrossRefGoogle Scholar
  17. 17.
    Lee SH, Chen SA, Wu TJ, Chiang CE, Cheng CC, Tai CT, Chiou CW, Ueng KC, Chang MS (1995) Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 76:675–678CrossRefGoogle Scholar
  18. 18.
    Peleg D, Orvieto R, Ferber A, Ben-Rafael Z (1998) Maternal supraventricular tachycardia recorded as apparent fetal heart rate in a case of fetal demise. Acta Obstet Gynecol Scand 77:786–787PubMedGoogle Scholar
  19. 19.
    Elkayam U, Goodwin TM (1995) Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol 75:521–523CrossRefGoogle Scholar
  20. 20.
    Doig JC, McComb JM, Reid DS (1992) Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 67:266–268CrossRefGoogle Scholar
  21. 21.
    Ferguson JD, Helms A, Mangrum JM, DiMarco JP (2011) Ablation of incessant left atrial tachycardia without fluoroscopy in a pregnant woman. J Cardiovasc Electrophysiol 22:346–349CrossRefGoogle Scholar
  22. 22.
    European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, ESC Committee for Practice Guidelines (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360–1420CrossRefGoogle Scholar
  23. 23.
    Burkart TA, Kron J, Miles WM, Conti JB, Gonzalez MD (2007) Successful termination of atrial flutter by ibutilide during pregnancy. Pacing Clin Electrophysiol 30:283–286CrossRefGoogle Scholar
  24. 24.
    Kockova R, Kocka V, Kiernan T, Fahy GJ (2007) Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol 18:545–547CrossRefGoogle Scholar
  25. 25.
    Konishi H, Miyoshi T, Neki R, Fukuda T, Ishibashi-Ueda H, Ogo T, Nakanishi N, Yoshimatsu J (2015) Intrapartum temporary inferior vena cava filters are rarely indicated in pregnant women with deep venous thromboses. J Vasc Surg Venous Lymphat Disord 3:370–375CrossRefGoogle Scholar
  26. 26.
    Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC (2006) Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 97:1206–1212CrossRefGoogle Scholar
  27. 27.
    Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P, Spirito P (2002) Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 40:1864–1869CrossRefGoogle Scholar
  28. 28.
    Tanaka H, Kamiya C, Katsuragi S, Tanaka K, Miyoshi T, Tsuritani M, Yoshida M, Iwanaga N, Neki R, Yoshimatsu J, Ikeda T (2014) Cardiovascular events in pregnancy with hypertrophic cardiomyopathy. Circ J 78:2501–2506CrossRefGoogle Scholar
  29. 29.
    Bauce B, Daliento L, Frigo G, Russo G, Nava A (2006) Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet Gynecol Reprod Biol 127:186–189CrossRefGoogle Scholar
  30. 30.
    Hankins GD, Wendel GD Jr, Leveno KJ, Stoneham J (1985) Myocardial infarction during pregnancy: a review. Obstet Gynecol 65:139–146PubMedGoogle Scholar
  31. 31.
    Tateno S, Niwa K, Nakazawa M, Akagi T, Shinohara T, Yasuda T, Study Group for Arrhythmia Late after Surgery for Congenital Heart Disease (ALTAS-CHD) (2003) Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 67:992–997CrossRefGoogle Scholar
  32. 32.
    Kamiya CA, Yoshimatsu J, Ikeda T (2016) Peripartum cardiomyopathy from a genetic perspective. Circ J 25(80):1684–1688CrossRefGoogle Scholar
  33. 33.
    Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J 3rd, McNamara DM, Seidman CE, Seidman JG, Arany Z, IMAC-2 and IPAC Investigators (2016) Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 21(374):233–241CrossRefGoogle Scholar
  34. 34.
    Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, American College of Cardiology/American Heart Association Task Force, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association, Heart Rhythm Society (2006) ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e385–e484CrossRefGoogle Scholar
  35. 35.
    Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781–788CrossRefGoogle Scholar
  36. 36.
    Lemery R, Brugada P, Bella PD, Dugernier T, van den Dool A, Wellens HJ (1989) Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation 79:990–999CrossRefGoogle Scholar
  37. 37.
    Brodsky M, Doria R, Allen B, Sato D, Thomas G, Sada M (1992) New-onset ventricular tachycardia during pregnancy. Am Heart J 123(4 Pt 1):933–941CrossRefGoogle Scholar
  38. 38.
    Cleary-Goldman J, Salva CR, Infeld JI, Robinson JN (2003) Verapamil-sensitive idiopathic left ventricular tachycardia in pregnancy. J Matern Fetal Neonatal Med 14:132–135CrossRefGoogle Scholar
  39. 39.
    Dalvi BV, Chaudhuri A, Kulkarni HL, Kale PA (1992) Therapeutic guidelines for congenital complete heart block presenting in pregnancy. Obstet Gynecol 79(5 (Pt 2)):802–804PubMedGoogle Scholar
  40. 40.
    Hidaka N, Chiba Y, Fukushima K, Wake N (2011) Pregnant women with complete atrioventricular block: perinatal risks and review of management. Pacing Clin Electrophysiol 34:1161–1176CrossRefGoogle Scholar
  41. 41.
    Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, Schwartz PJ, Andrews M (1998) Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS investigators. Circulation 97:451–456CrossRefGoogle Scholar
  42. 42.
    Shimizu W, Tanabe Y, Aiba T, Inagaki M, Kurita T, Suyama K, Nagaya N, Taguchi A, Aihara N, Sunagawa K, Nakamura K, Ohe T, Towbin JA, Priori SG, Kamakura S (2002) Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 39:1984–1991CrossRefGoogle Scholar
  43. 43.
    Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF, Hauer RN, Beckmann BM, Spazzolini C, Rordorf R, Rydberg A, Clur SA, Fischer M, van den Heuvel F, Kääb S, Blom NA, Ackerman MJ, Schwartz PJ, Wilde AA (2012) Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 60:2092–2099CrossRefGoogle Scholar
  44. 44.
    Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ (2014) Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol 64:1352–1358CrossRefGoogle Scholar
  45. 45.
    Food and Drug Administration, HHS (2014) Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist 79:72063–72103Google Scholar
  46. 46.
    Joglar JA, Page RL (2014) Management of arrhythmia syndromes during pregnancy. Curr Opin Cardiol 29:36–44CrossRefGoogle Scholar
  47. 47.
    Cox JL, Gardner MJ (1993) Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 36:137–178CrossRefGoogle Scholar
  48. 48.
    Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC Sr, Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J, American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing (2014) Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 129:2183–2242CrossRefGoogle Scholar
  49. 49.
    Horigome H, Takahashi MI, Asaka M, Shigemitsu S, Kandori A, Tsukada K (2000) Magnetocardiographic determination of the developmental changes in PQ, QRS and QT intervals in the foetus. Acta Paediatr 89:64–67CrossRefGoogle Scholar
  50. 50.
    Easterling TR, Brateng D, Schmucker B, Brown Z, Millard SP (1999) Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 93:725–733PubMedGoogle Scholar
  51. 51.
    Frishman WH, Chesner M (1988) Beta-adrenergic blockers in pregnancy. Am Heart J 115:147–152CrossRefGoogle Scholar
  52. 52.
    Lydakis C, Lip GY, Beevers M, Beevers DG (1999) Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12:541–547CrossRefGoogle Scholar
  53. 53.
    Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG (1997) Effect of atenolol on birth weight. Am J Cardiol 79:1436–1438CrossRefGoogle Scholar
  54. 54.
    Strasburger JF, Cuneo BF, Michon MM, Gotteiner NL, Deal BJ, McGregor SN, Oudijk MA, Meijboom EJ, Feinkind L, Hussey M, Parilla BV (2004) Amiodarone therapy for drug-refractory fetal tachycardia. Circulation 109:375–379CrossRefGoogle Scholar
  55. 55.
    Lomenick JP, Jackson WA, Backeljauw PF (2004) Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol 24:397–399CrossRefGoogle Scholar
  56. 56.
    Wang YC, Chen CH, Su HY, Yu MH (2006) The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 126:268–269CrossRefGoogle Scholar
  57. 57.
    Barnes EJ, Eben F, Patterson D (2002) Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 109:1406–1407CrossRefGoogle Scholar
  58. 58.
    Patel SJ, Reede DL, Katz DS, Subramaniam R, Amorosa JK (2007) Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. Radiographics 27:1705–1722CrossRefGoogle Scholar
  59. 59.
    Best PJ, Skelding KA, Mehran R, Chieffo A, Kunadian V, Madan M, Mikhail GW, Mauri F, Takahashi S, Honye J, Hernández-Antolín R, Weiner BH, Society for Cardiovascular Angiography & Interventions’ Women in Innovations (WIN) group (2011) SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. Catheter Cardiovasc Interv 77:232–241CrossRefGoogle Scholar
  60. 60.
    Tuzcu V, Kilinc OU (2012) Implantable cardioverter defibrillator implantation without using fluoroscopy in a pregnant patient. Pacing Clin Electrophysiol 35:e265–e266CrossRefGoogle Scholar
  61. 61.
    Natale A, Davidson T, Geiger MJ, Newby K (1997) Implantable cardioverter-defibrillators and pregnancy: a safe combination? Circulation 96:2808–2812CrossRefGoogle Scholar
  62. 62.
    Miyoshi T, Kamiya CA, Katsuragi S, Ueda H, Kobayashi Y, Horiuchi C, Yamanaka K, Neki R, Yoshimatsu J, Ikeda T, Yamada Y, Okamura H, Noda T, Shimizu W (2013) Safety and efficacy of implantable cardioverter-defibrillator during pregnancy and after delivery. Circ J 77:1166–1170CrossRefGoogle Scholar
  63. 63.
    Frett JD (2015) Wearable cardioverter defibrillator for peripartum cardiomyopathy patients. Eur J Heart Fail 17:234CrossRefGoogle Scholar
  64. 64.
    Reuschel E, Baessler A, Stöllberger C, Finsterer J, Maier L, Fischer M, Poschenrieder F, Heissenhuber F, Kurzidim K, Schepp CP, Badelt G, Seelbach-Göbel B (2016) Interdisciplinary management of left ventricular hypertrabeculation/noncompaction during pregnancy with a wearable defibrillator. Int J Cardiol 15(223):154–158CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2019

Authors and Affiliations

  • Takekazu Miyoshi
    • 1
  1. 1.Clinical Research Support CenterMie University HospitalTsuJapan

Personalised recommendations